http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101154276-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 2007-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101154276-B1 |
| titleOfInvention | Nerve Elongation Promoter and Elongation Inhibitor |
| abstract | The present invention is intended to contribute to the description of the mechanism of neuralgia after shingles and to provide a means for promoting regeneration of damaged nerves. In addition, the present invention is effective in the prevention or treatment of shingles neuralgia, chronic pain, postherpetic neuralgia, stroke, degenerative diseases, or the like caused by neuronal cell death accompanying any of the above diseases, and has fewer side effects. It is intended to provide a means for having. Neurite elongation promoters comprise as active ingredients an antibody that recognizes an early protein just prior to the varicella-zoster virus and cross-reacts with brain-derived neurotrophic factors; Prophylactic or therapeutic agents for neurological diseases comprise antibodies as active ingredients; Neurite elongation inhibitors comprise as active ingredients inhibitory antibodies that recognize the early protein just prior to the varicella-zoster virus and inhibit brain-derived neurotrophic factors; Prophylactic or therapeutic agents for diseases involving neurosensitivity caused by a condition selected from the group consisting of neuralgia, chronic pain, experience-dependent social aversion and stress after shingles include inhibitory antibodies as active ingredients. |
| priorityDate | 2006-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 910.